G-CSF Limitations: These agents essentially overstimulate a bone marrow that is already damaged by chemotherapy. Furthermore, ...
The FDA has granted priority review to the new drug application (NDA) for gedatolisib, a first-in-class multi-target ...
Cervical cancer treatment evolves with molecular screening and immunotherapies, emphasizing early detection as key to ...
Cervical cancer treatment evolves with molecular screening and immunotherapies, emphasizing early detection as key to ...
The GOG 3026 trial demonstrated that ribociclib and letrozole combination therapy achieved a 31% response rate and 84% ...
This episode of Treating Together, hosted by Chandler Park, MD, featuring guests Benjamin Garmezy, MD, and Manoj Bupathi, MD, ...
Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...
Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...
The FDA has granted breakthrough therapy designation (BTD) to sofetabart mipitecan (LY4170156) for the treatment of patients ...
Treatment with nivolumab (Opdivo) had limited benefit in patients with multiple myeloma (MM) or non-Hodkin lymphoma (NHL) ...
In an interview with Targeted Oncology, George Mulligan, PhD, discussed the key takeaways from analysis of the Immune Atlas ...
The FDA has granted breakthrough therapy designation (BTD) to soficabtagene geleucel (sofi-cel; WU-CART-007) for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results